The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes Across a Wide Range of Concentrations

PURPOSE: PLX4032 (RG7204), an oncogenic BRAF kinase inhibitor undergoing clinical evaluation, has high response rates in early clinical trials in patients with advanced BRAF(V600E) mutant melanoma. Combining PLX4032 with immunotherapy may allow expanding the durability of responses. The effects of P...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Comin-Anduix, Begoña, Chodon, Thinle, Sazegar, Hooman, Matsunaga, Douglas, Mock, Stephen, Jalil, Jason, Escuin-Ordinas, Helena, Chmielowski, Bartosz, Koya, Richard C., Ribas, Antoni
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057460/
https://ncbi.nlm.nih.gov/pubmed/21169256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1911
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы